NCT04666740View on ClinicalTrials.gov

A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

December 18, 2020

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Metastatic Pancreatic Ductal AdenocarcinomaHomologous Recombination Deficiency (HRD)
Interventions
DRUG

Pembrolizumab

Pembrolizumab 200 mg IV every 3 week. After the first 6 months (8 cycles), on C9D1 Pembrolizumab 400 mg IV every 6 week.

DRUG

Olaparib

Olaparib 300 mg twice day orally daily continuously (POLAR) as a maintenance therapy. After the first 6 months (8 cycles), on C9D1 olaparib 300 mg twice a day orally will be continued.

Trial Locations (7)

10065

Memorial Sloan Kettering Basking Ridge (All protocol activities), New York

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison

11553

Memorial Sloan Kettering Nassau (All protocol activities), Rockville Centre

11725

Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities), Commack

07748

Memorial Sloan Kettering Monmouth (All protocol activities), Middletown

07645

Memorial Sloan Kettering Bergen (All protocol activities), Montvale

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT04666740 - A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy | Biotech Hunter | Biotech Hunter